Page 6 - emap_newsletter_V2

eMAP – electronic EHA Medical HemAtology Program

WATCH WATCH
DR. KURUVILLA’S IN-DEPTH PRESENTATION OF THIS DR. KURUVILLA’S THOUGHTS ON THE RELEVANCE OF
ABSTRACT (~12 MINUTES) THESE DATA TO CANADIAN PRACTICE (~2 MINUTES)

CLICK HERE FOR THE LINK TO THE FULL ABSTRACT

Long-Term Survivors After Failure of CAR T cell Therapy for R/R Large B-cell
Lymphoma (LBCL): A GLA/DRST Study

Derigs P, et al. Presented at EHA 2022 Congress. Abstract P1448.

As long-term outcomes of patients with LBCL who
relapse or progress after CD19-directed CAR T cell
therapy with axi-cel or tisa-cel is limited, the objective
of this real world analysis was to examine patient
characteristics, relapse patterns, and management
strategies in those surviving one year or longer after
having failed CAR T cell therapy from a large German
Registry for Stem Cell Transplantation (GLA/DRST).

The OS at 12 months of 143 patients who failed CAR
T cell therapy was 22%. There were no significant
differences in survival between axi-cel and tisa-cel
failures (see Figure).

After having failed CAR T cell therapy, 18% of patients HR, hazard ratio; OS, overall survival.
survived =12 months (an additional 6% were alive but
had not reached the 12-month landmark), while 76%
died within the first year. Long-term survivors vs. those
who did not survive past 12 months differed significantly
in some characteristics (see Patient Characteristics
table).

TABLE OF CONTENTS 6